Hims & Hers Health, Inc. (HIMS) — Fair Value Analysis

Base-case fair value (P50): $22.73 · Current price: $28.27 · Verdict: Overvalued

The Verdict on HIMS

Our Monte Carlo simulations indicate that HIMS HERS HEALTH INC CLASS A (HIMS) is currently overvalued. The stock is trading at $28.27, a notable premium to its median fair value (P50) of $22.73. This represents a -19.6% downside from the current price to the calculated P50. Investors should note this substantial gap when considering the current valuation, as the models suggest a significant correction may be warranted to align with intrinsic value.

How HIMS stacks up against peers

Despite its current market valuation, HIMS exhibits an average quality tier in terms of its operational and financial health relative to its sector peers. While an "average" rating suggests stability, it doesn't necessarily justify the premium at which HIMS is trading. The disconnect between the current price of $28.27 and the median fair value of $22.73 suggests that the market may be pricing in growth expectations that are not fully supported by our fundamental models, even for a company with average sector standing.

What this means for investors

Given that HIMS is deemed overvalued with a -19.6% differential from its current $28.27 price to the $22.73 median fair value, investors should approach the stock with caution. The average quality tier provides a baseline understanding of its operational resilience, but the Monte Carlo simulations point to a significant overextension in valuation. A downside scenario, where the stock gravitates towards its fair value, presents a clear risk. Sign up for a free FairCurve account to see the full bear/bull distribution and track HIMS's fair value as new fundamentals are released.